CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Jeisys Medical Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Jeisys Medical Inc
76, Eulji-ro, Jung-gu
Phone: +82 226036417p:+82 226036417 SEOUL, 08501  South Korea Ticker: 287410287410

Business Summary
Jeisys Medical Inc, formerly Yuanta 3 Special Purpose Acquisition Co Ltd, a Korea-based company principally engaged in the manufacturing and distribution of medical devices. The Company manufactures and sells skin care medical devices such as ULTRAcel Q+, POTENZA, and other products. In addition, the Company also provides consumables such as cartridges and tips.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/202212/31/2021Yes----

General Information
Outstanding Shares: 71,168,424 (As of 6/30/2022)
Shareholders: 26,980
Stock Exchange: KDQ
Fax Number: +82 237702686


Copyright © 2022 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, October 7, 2022